Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Yusuf Saleeby

General Practice Murrells Inlet, SC Medical Doctor

NPI 1558324053 CMS profile 777731

637-C Bellamy Ave, Murrells Inlet, SC 29576

Open in the dashboard

General payments

$1,140

46 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yusuf Saleeby of Murrells Inlet, SC is reported in the CMS Open Payments database as having received $1,140 across 46 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $213 12
2023 General $197 9
2022 General $74 3
2021 General $20 1
2020 General $385 16
2019 General $251 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yusuf Saleeby
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Yusuf Saleeby were reported at $213. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Yusuf Saleeby General Practice median Middle half National median
2019 $251 $107 $37–$285 $163
2020 $385 $75 $25–$213 $114
2021 $20 $93 $30–$272 $132
2022 $74 $103 $36–$279 $149
2023 $197 $106 $34–$276 $160
2024 $0 $114 $39–$290 $164
2025 $213 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Romark Laboratories, LC $482 18 payments
  2. QOL Medical, LLC $374 20 payments
  3. AstraZeneca Pharmaceuticals LP $119 1 payment
  4. Pfizer Inc. $62 2 payments
  5. ANI Pharmaceuticals, Inc. $31 1 payment
  6. Alfasigma USA, Inc. $20 1 payment
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $19 1 payment
  8. Ferring Pharmaceuticals Inc. $16 1 payment
  9. Amarin Pharma Inc. $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,105 45 payments
  2. Education $35 1 payment
Products named General payments · program years 2019–2025
  1. ALINIA Gastroenterology $482 18 payments
  2. ALINIA Gastroenterology $482 18 payments
  3. ALINIA Gastroenterology $482 18 payments
  4. Sucraid Genetic Disease $197 11 payments
  5. Sucraid Therapy For Csid $166 8 payments
  6. FARXIGA $119 1 payment
  7. EUCRISA $62 2 payments
  8. PURIFIED CORTROPHIN GEL $31 1 payment
  9. CIBINQO $27 1 payment
  10. COMIRNATY $27 1 payment
  11. Other $90 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

294

Median for General Practice: 1,105

Drug cost

$27,045

Median for General Practice: $48,734

Branded share of claims

32.7%

Median for General Practice: 17.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 12 $15,320
Liothyronine Sodium Generic 87 $4,425
Armour Thyroid Thyroid,pork Brand 24 $2,206
Np Thyroid Thyroid,pork Brand 37 $2,002
Progesterone Progesterone, Micronized Brand 12 $807
Hydrocortisone Generic 19 $553
Testosterone Cypionate Generic 12 $553
Ezetimibe Generic 11 $358
Tamsulosin Hcl Generic 12 $197
Niva Thyroid Thyroid,pork Brand 11 $197

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.

Records

46 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record